One Comment

  1. James Peters says:

    GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (CBD). The study was in patients with Dravet syndrome which is a rare and severe form of epilepsy in children with no FDA approved treatments http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=960348 GW are also conducting three other Phase III trials into different types of epilepsy as well. All the results from these should be out by the end of this year. I know GW are hoping to get this and Sativex approved in the US.

Leave a Reply

Your email address will not be published. Required fields are marked *